Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Circulating Tumor DNA Assessment in Early-Stage Endometrial Cancer (SIGNAL-EMC 101)

NCT07339384 is registered in ClinicalTrials.gov with Natera, Inc. as lead sponsor.

NCT NCT07339384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07339384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Circulating Tumor DNA Assessment in Early-Stage Endometrial Cancer (SIGNAL-EMC 101)
Lead sponsor
Natera, Inc.
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
October 31, 2034
Enrollment
1,010 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer